Q4B Annex 6 Uniformity of Dosage Units General ChapterQ4B附录6 统一剂量单位 常规篇
VIP免费
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL
REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
ICH HARMONISED TRIPARTITE GUIDELINE
EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
TEXTS FOR USE IN THE ICH REGIONS
ON
UNIFORMITY OF DOSAGE UNITS GENERAL CHAPTER
Q4B ANNEX 6
Current
Step 4
version
dated 13 November 2013
This Guideline has been developed by the appropriate ICH Expert Working Group
and has been subject to consultation by the regulatory parties, in accordance with the
ICH Process. At Step 4 of the Process the final draft is recommended for adoption to
the regulatory bodies of the European Union, Japan and USA.
Q4B Annex 6
Document History
Code
History
Date
Q4B Annex 6
Approval by the Steering Committee under
Step 2
and release
for public consultation.
13 November
2008
Q4B Annex
6(R1)
Integration into
Step 2
of the Health Canada
Interchangeability Statement under Section 4.5 after
approval by the Steering Committee.
27 September
2010
Current
Step 4
version
Q4B Annex 6
Approval by the Steering Committee under
Step 4
and
recommendation for adoption to the three ICH regulatory
bodies. The R was removed from the name of the document as
this is the first version of the Annex 6
Step 4.
13 November
2013
i
EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
TEXTS FOR USE IN THE ICH REGIONS
ON
UNIFORMITY OF DOSAGE UNITS GENERAL CHAPTER
Q4B ANNEX 6
ICH Harmonised Tripartite Guideline
Having reached
Step 4
of the ICH Process at the ICH Steering Committee meeting on 13
November 2013, this guideline is recommended for adoption
to the three regulatory parties to ICH.
TABLE OF CONTENTS
1. INTRODUCTION...................................................................................................... 1
2. Q4B OUTCOME ........................................................................................................ 1
2.1 Analytical Procedures .................................................................................................... 1
2.2 Acceptance Criteria ....................................................................................................... 1
3. TIMING OF ANNEX IMPLEMENTATION .............................................................. 1
4. CONSIDERATIONS FOR IMPLEMENTATION ...................................................... 1
4.1 General Consideration ................................................................................................... 1
4.2 FDA Consideration ........................................................................................................ 1
4.3 EU Consideration .......................................................................................................... 2
4.4 MHLW Consideration .................................................................................................... 2
4.5 Health Canada Consideration ....................................................................................... 2
5. REFERENCES USED FOR THE Q4B EVALUATION ............................................. 2
标签: #附录
摘要:
展开>>
收起<<
INTERNATIONALCONFERENCEONHARMONISATIONOFTECHNICALREQUIREMENTSFORREGISTRATIONOFPHARMACEUTICALSFORHUMANUSEICHHARMONISEDTRIPARTITEGUIDELINEEVALUATIONANDRECOMMENDATIONOFPHARMACOPOEIALTEXTSFORUSEINTHEICHREGIONSONUNIFORMITYOFDOSAGEUNITSGENERALCHAPTERQ4BANNEX6CurrentStep4versiondated13November2013ThisGuide...
声明:如果您的权利被侵害,请联系我们的进行举报。
相关推荐
-
浅析体外诊断试剂成品检验及留样检验的若干要求
2024-05-21 115 -
浅谈螺杆桩螺纹段长度对承载力的影响
2024-05-21 85 -
溶解细菌纤维素的方法VIP免费
2024-05-21 92 -
Box-Cox变换及其在STATA软件中的实现VIP免费
2024-07-10 110 -
IEC60601-1-2_...电放电抗扰度测试变化及对策VIP免费
2025-04-12 71 -
9.2025年版《中国药典》四部理化分析通用技术要求增修订概况
2025-04-12 56 -
8.2025年版《中国药典》(四部)通用技术要求和指导原则增修订概况
2025-04-12 92 -
7.2025年版《中国药典》三部通则0237国家生物标准物质研制解读
2025-04-12 103 -
6.2025年版《中国药典》三部关于异常毒性检查修订内容的解读
2025-04-12 81 -
医疗器械注册资料技术审评探讨VIP免费
2025-09-16 79
作者:冒牌货
分类:专业资料
价格:50质量币
属性:6 页
大小:62.85KB
格式:PDF
时间:2025-12-24

